Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 ...
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...
Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM ...
A $400 million, four-year Blackstone Life Sciences financing supports ongoing and future duvakitug development, with ...
In an era of overt sexism in the sciences, she made two major discoveries, including identifying a chemical signal in the ...
BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
India faces a growing crisis in wound treatment, driven by diabetes and an ageing population. A new policy approach could ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsSujal Patel - Co-Founder, ...
PROSERA Study Overview and Baseline Characteristics ...
Tampa Free Press on MSN
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study
San Diego-based Gossamer Bio released long-awaited Phase 3 data today for its drug seralutinib, revealing a complex set of results that both challenged and encouraged researchers. The PROSERA study, ...
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results